碳酸氢钠治疗重症监护病房严重代谢性酸血症患者(BICAR-ICU):一项多中心、开放标签、随机对照3期试验
BICAR-ICU是一项在法国26个ICU开展的多中心、开放标签、随机对照3期试验,纳入389例成人严重酸血症患者(pH≤7.20、PaCO2≤45 mmHg、碳酸氢钠浓度≤20 mmol/L,且SOFA总分≥4或动脉乳酸≥2 mmol/L)。患者1:1随机接受无碳酸氢钠(对照组)或4.2%碳酸氢钠静脉输注以维持动脉pH>7.30,方案推荐每次输注125-250 mL/30 min,纳入后24 h内最大1000 mL。主要终点(28天全因死亡和7天至少一个器官衰竭的复合终点)在对照组138/194(71%)与碳酸氢钠组128/195(66%)之间无显著差异(绝对差-5.5%,95%CI -15.2至4.2;p=0.24)。在预设AKIN评分2或3的急性肾损伤亚组中,碳酸氢钠组28天生存率显著高于对照组(54% [95%CI 45-65] vs 37% [28-48];p=0.0283)。代谢性碱中毒、高钠血症和低钙血症在碳酸氢钠组更常见,未报告危及生命的并发症。
要点
- 在严重代谢性酸血症(pH≤7.20、PaCO2≤45 mmHg、碳酸氢钠≤20 mmol/L)成人ICU患者中,碳酸氢钠对28天死亡和7天器官衰竭复合终点无显著影响(71% vs 66%,绝对差-5.5%,95%CI -15.2至4.2;p=0.24)。
- 预设AKIN评分2或3的急性肾损伤亚组中,碳酸氢钠组28天生存率显著高于对照组(54% [95%CI 45-65] vs 37% [28-48];p=0.0283)。
- 碳酸氢钠组代谢性碱中毒、高钠血症和低钙血症更常见,但未报告危及生命的并发症。
- 方案推荐4.2%碳酸氢钠静脉输注维持动脉pH>7.30,每次125-250 mL/30 min,纳入后24 h内最大1000 mL。
适用人群与场景
- 成人患者(年龄≥18岁),入住ICU 48小时内,严重酸血症:pH≤7.20、PaCO2≤45 mmHg、碳酸氢钠浓度≤20 mmol/L,且SOFA总分≥4或动脉乳酸≥2 mmol/L。
- 法国26个ICU的多中心研究人群。
诊断标准与关键阈值
- 严重酸血症诊断标准:pH≤7.20、PaCO2≤45 mmHg、碳酸氢钠浓度≤20 mmol/L。
- 纳入还需SOFA总分≥4或动脉乳酸浓度≥2 mmol/L。
- AKIN评分2或3为预设急性肾损伤亚组分层标准。
处置流程与药物剂量
- 碳酸氢钠组:4.2%碳酸氢钠静脉输注,以维持动脉pH>7.30为目标。
- 方案推荐每次输注量125-250 mL,30分钟内输完,纳入后24小时内最大1000 mL。
- 对照组:不给予碳酸氢钠。
研究设计与关键结果
- 多中心、开放标签、随机对照3期试验,纳入389例意向治疗人群(对照组194例,碳酸氢钠组195例)。
- 主要复合终点(28天全因死亡和7天至少一个器官衰竭):对照组138/194(71%)vs 碳酸氢钠组128/195(66%),绝对差-5.5%(95%CI -15.2至4.2;p=0.24),无显著差异。
- 28天生存概率Kaplan-Meier估计:对照组46%(95%CI 40-54)vs 碳酸氢钠组55%(49-63),p=0.09,无显著差异。
- 预设AKIN评分2或3亚组28天生存率:对照组37%(95%CI 28-48)vs 碳酸氢钠组54%(45-65),p=0.0283,碳酸氢钠组显著较高。
- 不良事件:代谢性碱中毒、高钠血症和低钙血症在碳酸氢钠组更常见,未报告危及生命的并发症。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机对照3期试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在严重代谢性酸血症成人ICU患者中,碳酸氢钠未改善总体主要复合终点,不应常规用于所有此类患者。
- 对AKIN评分2或3的急性肾损伤亚组患者,碳酸氢钠可能降低主要复合终点和28天死亡率(作者结论)。
- 使用碳酸氢钠时需监测代谢性碱中毒、高钠血症和低钙血症。
指南或共识出处
- BICAR-ICU试验,ClinicalTrials.gov注册号NCT02476253,法国卫生部与法国麻醉与重症监护学会资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Acute acidaemia is frequently observed during critical illness. Sodium bicarbonate infusion for the treatment of severe metabolic acidaemia is a possible treatment option but remains controversial, as no studies to date have examined its effect on clinical outcomes. Therefore, we aimed to evaluate whether sodium bicarbonate infusion would improve these outcomes in critically ill patients.
METHODS: We did a multicentre, open-label, randomised controlled, phase 3 trial. Local investigators screened eligible patients from 26 intensive care units (ICUs) in France. We included adult patients (aged ≥18 years) who were admitted within 48 h to the ICU with severe acidaemia (pH ≤7·20, PaCO2 ≤45 mm Hg, and sodium bicarbonate concentration ≤20 mmol/L) and with a total Sequential Organ Failure Assessment score of 4 or more or an arterial lactate concentration of 2 mmol/L or more. We randomly assigned patients (1:1), by stratified randomisation with minimisation via a restricted web platform, to receive either no sodium bicarbonate (control group) or 4·2% of intravenous sodium bicarbonate infusion (bicarbonate group) to maintain the arterial pH above 7·30. Our protocol recommended that the volume of each infusion should be within the range of 125-250 mL in 30 min, with a maximum of 1000 mL within 24 h after inclusion. Randomisation criteria were stratified among three prespecified strata: age, sepsis status, and the Acute Kidney Injury Network (AKIN) score. The primary outcome was a composite of death from any cause by day 28 and the presence of at least one organ failure at day 7. All analyses were done on data from the intention-to-treat population, which included all patients who underwent randomisation. This study is registered with ClinicalTrials.gov, number NCT02476253.
FINDINGS: Between May 5, 2015, and May 7, 2017, we enrolled 389 patients into the intention-to-treat analysis in the overall population (194 in the control group and 195 in the bicarbonate group). The primary outcome occurred in 138 (71%) of 194 patients in the control group and 128 (66%) of 195 in the bicarbonate group (absolute difference estimate -5·5%, 95% CI -15·2 to 4·2; p=0·24). The Kaplan-Meier method estimate of the probability of survival at day 28 between the control group and bicarbonate group was not significant (46% [95% CI 40-54] vs 55% [49-63]; p=0·09. In the prespecified AKIN stratum of patients with a score of 2 or 3, the Kaplan-Meier method estimate of survival by day 28 between the control group and bicarbonate group was significant (37% [95% CI 28-48] vs 54% [45-65]; p=0·0283). [corrected] Metabolic alkalosis, hypernatraemia, and hypocalcaemia were observed more frequently in the bicarbonate group than in the control group, with no life-threatening complications reported.
INTERPRETATION: In patients with severe metabolic acidaemia, sodium bicarbonate had no effect on the primary composite outcome. However, sodium bicarbonate decreased the primary composite outcome and day 28 mortality in the a-priori defined stratum of patients with acute kidney injury.
FUNDING: French Ministry of Health and the Société Française d'Anesthésie Réanimation.
参考来源
- Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet. 2018. PMID: 29910040. doi:10.1016/S0140-6736(18)31080-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。